

Aviso de Derechos para emisoras del

FECHA: 19/06/2024

BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:

FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO	235980
FOLIO DE REFERENCIA INDEVAL	729727C002
TIPO DE MENSAJE	Replace
COMPLETO / INCOMPLETO	COMPLETE
CONFIRMADO / NO CONFIRMADO	CONFIRMED

CLAVE DE COTIZACIÓN	DMTK
RAZÓN SOCIAL	DERMTECH, INC.
SERIE	*
ISIN	US24984K1051
MERCADO PRINCIPAL	NASDAQ

TIPO DE EVENTO	BANKRUPTCY
-----------------------	------------

MANDATORIO / OPCIONAL / VOLUNTARIO	Mandatory
FECHA EFECTOS	18/06/2024

NOTAS DEL EVENTO CORPORATIVO

NOTA
(19/06/2024) SAN DIEGO(BUSINESS WIRE)Jun. 18, 2024, DermTech, Inc. a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. USFINRA dailyListDatetime 18 06 2024 dailyListReasonDescription Symbol Change newSymbolCode DMTWQ oldSymbolCode DMTKW newSecurityDescription DERMTECH INC Warrant 08 29 2024 oldSecurityDescription DERMTECH INC Warrant 08 29 2024 exDate 20 06 2024
(18/06/2024)

Aviso de Derechos para emisoras del

FECHA: 19/06/2024

USNW DermTech Files for Voluntary Chapter 11 Protection 2024.06.18 08.05 ET . News Release Company Website. <https://www.dermtech.com> SAN DIEGO (Business Wire) DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DMT), while simultaneously conducting a process to sell substantially all of its assets.

Through the bankruptcy process, the Company intends to safeguard the interest of stakeholders and maximize the value of its assets. DermTech is advised in this matter by Wilson, Sonsini, Goodrich and Rosati, PC, AlixPartners, Inc., and TD Cowen, a division of TD Securities. Alongside the chapter 11 filings, the Company also implemented a reduction in force (RIF) to significantly reduce expenses associated with its current operations to preserve cash.

This RIF resulted in an immediate workforce reduction of approximately 15 employees (approximately 20% of the Company's workforce), with potential additional reductions of DermTech's workforce in the future. Case Title Court Case No Chp Date Filed Closed Disposition DermTech, Inc. Delaware 1:24-bk-11378 11 06 18 2024